



1st February 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	16466.3	+2.47%	-7.61%
S&P 500	1940.24	+2.48%	-5.76%
Nasdaq	4613.95	+2.38%	-2.58%
Nikkei	17865.23	+1.98%	+0.39%
Stoxx 600	342.273	+2.21%	-0.08%
CAC 40	4417.02	+2.19%	+3.38%
Oil /Gold			
Crude WTI	33.69	+0.45%	-37.40%
Gold (once)	1117.15	+0.04%	-5.83%
Currencies/Rates			
EUR/USD	1.08205	-1.09%	-10.58%
EUR/CHF	1.1087	-0.03%	-7.79%
German 10 years	0.266	-20.53%	-50.86%
French 10 years	0.655	-10.36%	-21.82%
Euribor	-0.162	+1.25%	-307.69%

Economic releases :

Date	
1st-Feb	CNY - PMI (49.4 A, 49.6 E) FR - Manuf PMI Jan. (50 E) GB - PMI Manuf. Jan (51.6 E) US - Personal consumption Exp. Core dec. (1.4% E y/y) US - ISM Manuf. JAN. (48.5 E) US - Construction Spending Dec. (0.6% E)

Upcoming BG events :

Date	
4th-Feb	QIAGEN (BG Paris With CFO, IR)
2nd-Mar	ALBIOMA (BG Paris Lunch CEO)
10th-Mar/ 11th-Mar	BG TMT Conference
23rd-Mar	EIFFAGE (BG Luxembourg with IR)
28th-Apr	ORPEA (BG Luxembourg with IR)

Recent reports :

Date	
27th-Jan	GSK : A balanced story with most risks now behind us
25th-Jan	BioTechnology Last mark down on biotech!
20th-Jan	SAINT GOBAIN : France likely to be a positive catalyst in 2016
19th-Jan	The wild child comes of age: thank you Orange!
15th-Jan	QIAGEN : Leverage would have to wait
13th-Jan	A spicier dish (Nestlé, coverage initiation)

List of our Reco & Fair Value : Please click here to download



WORLDPAY

NEUTRAL Coverage initiated, Fair Value 290p (-7%)

An aisle-end stock, but not a bargain (full report out today)

We are initiating Worldpay with a Neutral recommendation and a FV of 290p (downside of 7%). While its offer corresponds well to current demand from merchants, we estimate its recurring sales, the rising share of e-commerce in the mix and potential to improve EBITDA are already priced in. After gaining +30% since its IPO on 13th October 2015, the share harbours no upside even when looking just at EV/sales and EV/EBITDA multiples until 2016e (namely until the end of the plan to invest in the platforms). The share is trading on an average premium relative to peers of 22% for 2016e. Research Report out today.

ACCORHOTELS

BUY-Top Picks, Fair Value EUR48 vs. EUR53 (+37%)

BUY-Top pick confirmed even in a "Stress" scenario

Despite very positive trends in tourism market expectations and a challenging short term environment, especially in two main geographies for AccorHotels i.e. France (29% of no. of rooms) and Brazil (over 7% of the offer) weighing on results, the current impact on valuation looks excessive in our view. [slideshow presentation here](#)

LUXOTTICA

BUY, Fair Value EUR65 vs. EUR66 (+13%)

Q4 sales publication overshadowed by co-CEO for Markets' departure

Last Friday, Luxottica announced Q4 15 adj. sales of EUR2,059m (+8.9% as reported and +2.7% adj FX-n) which came shy of CS and our expectations by ~3% only because of a higher impact from the realignment of the retail calendar and the 53rd week last year (adj FX-n growth of 7.7% excl. those calendar effects) whose impact is on U.S retail only (-2.7% adj. FX-n / +7.7% excl. calendar effect). The breaking news was clearly the departure of co-CEO for Markets Mr Khan as Mr Del Vecchio and him acknowledged that LUX was not fully capturing the significant growth prospects because of this co-CEO structure. Therefore Mr Khan will be replaced by Mr Del Vecchio whilst Mr Vian remains CEO for Product & Operations. In our view this announcement will revive some issues about the governance, especially from those who were dubious about this co-CEO structure, we adopt the same stance than during the previous "governance crisis" (Sep-Nov 2014): the business model and strategy remain sound. All eyes are now be turned towards the ID on 2nd March! Our new FV of EUR65 reflects slight adjustments on our FY15-16 EBIT forecasts (-1%) but Buy recommendation reiterated.

LVMH

BUY, Fair Value EUR182 (+23%)

Sales growth slowdown expected in Q4 (inc at LV) and FY 50bp margin delineline anticipated

LVMH will report its FY 15 results on Tuesday February 2nd (after market closure with analyst meeting to follow). We expect sales to reach EUR35.45bn (CS: 35.55bn) and to grow 5% organically (+3% in Q4 alone) and EBIT margin to be down 50bp to 18.2%. We reiterate our Buy recommendation with an unchanged EUR182 FV.

SAFILO

BUY, Fair Value EUR14 (+41%)

Safilo ended a difficult transition year, looking forward to seeing improvements in 2016!

Last Friday Safilo released an unexpected FY15 preliminary sales publication. FY sales came in at EUR1,279m (+8.5% as reported and flat FX-n) in line with our forecast (EUR1,280m) but below an overly-optimistic CS (EUR1,299m). However, the quality of top line growth in Q4 was lower we expected (-2.7% FX-n vs. +1.5%e) due to North America (retail, winter sport products) and Asia-Pacific (reset plan, H-K), despite a good acceleration in Europe. Although implementing the first initiatives to strengthen the organisation (loss of Kering's small licences, new distribution model in Asia-Pacific, etc.) proved to be more painful than initially thought, we are still optimistic for 2016 given sales and margin tailwinds.

THE SWATCH GROUP

NEUTRAL, Fair Value CHF420 vs. CHF440 (+21%)

Deterioration expected in H2

The Swatch Group will release its FY 2015 sales and results during the current week (likely Thursday). Ahead of this publication, we have slightly adjusted our sales and EBIT 2015-2016 estimations following the recent poor Swiss watches exports publications. Our 2015-16 EBIT estimates have been trimmed by almost 5%. Consequently, we have reduced our FV to CHF420 from CHF440 and we remain Neutral on the stock, given still weak visibility on watches industry.

In brief...

LAFARGEHOLCIM, Current Chairman about to leave, according to the Press
PERNOD RICARD, Acquisition of a majority stake in Monkey 47

TMT

Worldpay

Price 313.00p

An aisle-end stock, but not a bargain (full report out today)

Fair Value 290p (-7%)

NEUTRAL Coverage initiated

Bloomberg	WPG LN
Reuters	WPG.L
12-month High / Low (p)	316.8 / 240.0
Market Cap (GBP)	6,260
Ev (BG Estimates) (GBP)	7,644
Avg. 6m daily volume (000)	10,147
3y EPS CAGR	33.8%

We are initiating Worldpay with a Neutral recommendation and a FV of 290p (downside of 7%). While its offer corresponds well to current demand from merchants, we estimate its recurring sales, the rising share of e-commerce in the mix and potential to improve EBITDA are already priced in. After gaining +30% since its IPO on 13th October 2015, the share harbours no upside even when looking just at EV/sales and EV/EBITDA multiples until 2016e (namely until the end of the plan to invest in the platforms). The share is trading on an average premium relative to peers of 22% for 2016e. *Research Report out today.*

	1 M	3 M	6 M	31/12/15
Absolute perf.	3.0%	13.8%	ns	1.9%
Softw. & Comp.	-3.0%	1.8%	5.0%	-2.3%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

ANALYSIS

- Worldpay is a fintech, namely a software company operating in the payments segment. Former UK division of Royal Bank of Scotland (sold in 2010 to Bain and Advent for EV of GBP2bn), the group's core business is processing and acquiring payment transactions (in-store in the UK and US, and e-commerce on a global scale). Its offering targets a wide range of merchants (from small/medium-sized merchants to large retailers).
- Based on the number of card transactions processed at merchants, Worldpay is the no. 5 acquirer in the world (market share of 5%e), the no. 1 in Europe (market share of 20%e, with uncontested leadership status in the UK, market share of 42%) and no. 9 in the US (market share of 3%e). In e-commerce, we estimate it is the global leader (market share of 6%e) and the European no. 1 (market share of 20%e).

YEnd Dec. (GBPm)	2014	2015e	2016e	2017e
Sales	3,627	4,000	4,280	4,622
% change		10.3%	7.0%	8.0%
EBITDA	286	304	402	506
EBIT	296.3	335.0	376.6	422.5
% change		13.1%	12.4%	12.2%
Net income	91.7	126.1	233.8	273.9
% change		37.5%	85.5%	17.1%

	2014	2015e	2016e	2017e
Operating margin	8.2	8.4	8.8	9.1
Net margin	-1.4	-0.4	3.5	4.8
ROE	26.0	-2.2	17.8	21.7
ROCE	14.0	15.5	15.0	16.1
Gearing	-1,173	200.5	146.7	101.9

(p)	2014	2015e	2016e	2017e
EPS	5.71	6.30	11.69	13.70
% change	-	10.3%	85.5%	17.1%
P/E	54.8x	49.7x	26.8x	22.9x
FCF yield (%)	0.0%	NM	1.9%	3.7%
Dividends (p)	0.00	0.00	1.87	2.78
Div yield (%)	NM	NM	0.6%	0.9%
EV/Sales	2.3x	1.9x	1.8x	1.6x
EV/EBITDA	29.8x	25.1x	18.6x	14.4x
EV/EBIT	28.7x	22.8x	19.9x	17.3x

- We believe Worldpay's offers and technologies respond well to current issues at merchants, in both physical stores and in e-commerce. Indeed, merchants are looking for a multichannel solution enabling them to accept any payment type via any channel and in any currency and offering a secure and fluid purchasing experience. However, it still has everything to prove (current fundamentals are not impressive for the payments sector). Despite our far from pessimistic estimates, the share is expensive (even taking into account only EV/sales and EV/EBITDA multiples). We believe it will only be reliable to reason in PEG once investment in the platforms is complete, early 2017e. The share is trading on an average premium of 22% vs. its peers in 2016e.

VALUATION

- We are initiating coverage of Worldpay with a Neutral rating and a Fair Value of 290p (downside of 7%). This latter is made up of an equi-weighted average between three valuation methods (DCF at 317p, peer comparison at 285p, and sum of the parts at 268p).
- We advise investors to rather play the payments and security theme via Wirecard (Buy, FV EUR52, Q1 Top Pick), Worldline (Buy, FV of EUR29, Q1 Top Pick), and Ingenico Group (Buy, FV of EUR150).

NEXT CATALYSTS

- Full-year 2015 earnings: 8th March (before trading).

[Click here to download](#)



Analyst :
Richard-Maxime Beaudoux
33(0) 1.56.68.75.61
rmbeaudoux@bryangarnier.com

Sector Team :
Thomas Coudry
Gregory Ramirez
Dorian Terral

Hotels

AccorHotels

Price EUR35.00

BUY-Top pick confirmed even in a "Stress" scenario

Fair Value EUR48 vs. EUR53 (+37%)

BUY-Top Picks

Bloomberg	AC FP
Reuters	ACCP.PA
12-month High / Low (EUR)	51.3 / 32.2
Market Cap (EURm)	8,237
Ev (BG Estimates) (EURm)	8,390
Avg. 6m daily volume (000)	1 305
3y EPS CAGR	4.9%

Despite very positive trends in tourism market expectations and a challenging short term environment, especially in two main geographies for AccorHotels i.e. France (29% of no. of rooms) and Brazil (over 7% of the offer) weighing on results, the current impact on valuation looks excessive in our view.

AccorHotels is continuing to deploy its strategy, with the implementation of the digital plan, sustained growth in HotelServices and the transformation of HotelInvest. Moreover, AccorHotels has made major moves recently with the finalisation of the alliance with China Lodging and the agreement for the acquisition of FRHI.

	1 M	3 M	6 M	31/12/15
Absolute perf.	-13.1%	-24.0%	-23.1%	-12.5%
Travel&Leisure	-8.1%	-5.2%	-3.5%	-7.5%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

After some RevPAR adjustments due to short term uncertainties for our "Base Case" scenario, we have reduced our FV to EUR48 based on a DCF model i.e. upside of c. 40%. Assuming that things could get worse, we have defined a "Stress" scenario taking into account no RevPAR rebound in France in 2016, a further deterioration in Brazil and a slowdown in other geographies compared to 2015. In this case, our FV would be EUR42 nevertheless representing upside of 20%. We are confirming our Buy recommendation (slideshow presentation attached).

YEnd Dec. (€m)	2014	2015e	2016e	2017e
Sales	5,454	5,670	5,848	6,076
% change		4.0%	3.2%	3.9%
EBITDA	923	1,019	1,093	1,201
EBIT	602.0	667.2	741.5	837.0
% change		10.8%	11.1%	12.9%
Net income	386.0	442.3	470.1	536.7
% change		14.6%	6.3%	14.2%

ANALYSIS

- **A challenging short term environment weighing excessively on valuation in our view:** With France representing 29% of the total group offer in terms of the no. of rooms and Brazil over 7%, AccorHotels' earnings forecasts could come under pressure if we assume a slow recovery after 13th November terrorist attacks, hard competition from the sharing economy related to a lack of control and a worse deterioration in the economic situation especially in Brazil. However even in a such "Stress" scenario, the current valuation is difficult to justify.

	2014	2015e	2016e	2017e
Operating margin	11.0	11.8	12.7	13.8
Net margin	4.1	6.4	8.0	8.8
ROE	6.2	12.3	18.0	24.0
ROCE	12.4	15.6	19.4	25.2
Gearing	4.1	5.0	5.0	5.1

- **Our "Stress" scenario:** Taking into account such an environment in 2016, we have estimated RevPAR growth of 1.9% after 3.1% anticipated in 2015 with notably no rebound in France compared to 2015 (+1%) and higher negative RevPAR in the Americas due to Brazil (-6% after -5% in 2015). Our EBIT would reach EUR700m after EUR667m in 2015, up nearly 5% (group guidance for 2015 is between EUR655m and EUR675m). In all, based on a DCF, our FV would be EUR42 representing upside of 20%.

(€)	2014	2015e	2016e	2017e
EPS	1.68	1.92	1.70	1.94
% change	-	14.6%	-11.6%	14.2%
P/E	20.9x	18.2x	20.6x	18.1x
FCF yield (%)	7.5%	7.2%	7.4%	8.4%
Dividends (€)	0.95	1.00	1.10	1.25
Div yield (%)	2.7%	2.9%	3.1%	3.6%
EV/Sales	1.5x	1.5x	1.4x	1.4x
EV/EBITDA	9.1x	8.2x	7.7x	7.0x
EV/EBIT	13.9x	12.6x	11.3x	10.0x

- **Our "Base Case" scenario:** In this case, we have taken into account RevPAR growth of 4.5% in 2016 (vs. 4.8% previously). After a few difficult months following 13th November, we expect France to rebound and hotel activities to be sustained by major events i.e. the EURO 2016 football tournament in June and July or the motor show in Paris in October. In Brazil, the 2016 Summer Olympic Games should sustain RevPAR in a challenging economic environment. In all, our EBIT reaches EUR741m (w/o FRHI) and our DCF valuation points to a FV of EUR48 vs. EUR53.

VALUATION

- Our FV is based on a DCF valuation using our "Base Case" scenario forecasts. We use a WACC of 8.6% with a cost of capital of 8.7%, a growth to infinity of 2.5% with normal average EBIT margin of 15% as of 2025.
- At the current share price, the stock is trading at 2016e EV/EBITDA of 7.7x which compares with an average for European peers of 8.3x and 9.8x for US Hoteliers. Based on our FV, 2016e EV/EBITDA would stand at 10.5x and under our "Stress" scenario at 9.2x.

NEXT CATALYSTS

- FY 2015 results on 18th February

[Click here to download](#)



Analyst :
 Bruno de La Rochebrochard
 33(0) 1 56 68 75 88
 bdelarochebrochard@bryangarnier.com

Luxury & Consumer Goods

Luxottica

Price EUR57.55

Q4 sales publication overshadowed by co-CEO for Markets' departure

Fair Value EUR65 vs. EUR66 (+13%)

BUY

Bloomberg	LUX IM
Reuters	LUX.MI
12-month High / Low (EUR)	67.5 / 50.7
Market Cap (EURm)	27,834
Ev (BG Estimates) (EURm)	28,857
Avg. 6m daily volume (000)	744.2
3y EPS CAGR	15.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-6.0%	-10.1%	-13.5%	-4.7%
Consumer Gds	-4.5%	-5.3%	-4.7%	-3.4%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

YEnd Dec. (€m)	2014	2015e	2016e	2017e
Sales	7,652	8,837	9,550	10,209
% change		15.5%	8.1%	6.9%
EBITDA	1,542	1,891	2,113	2,303
Reported EBIT	1,158	1,421	1,580	1,734
% change		22.7%	11.2%	9.7%
Net income	642.6	843.7	967.9	1,078
% change		31.3%	14.7%	11.4%


	2014	2015e	2016e	2017e
EBIT margin (rep.)	15.1	16.1	16.5	17.0
Net margin	8.4	9.5	10.1	10.6
ROE	13.1	16.7	17.6	18.0
ROCE	10.4	13.1	14.7	16.1
Gearing	20.6	20.2	10.4	1.6

(€)	2014	2015e	2016e	2017e
EPS	1.44	1.76	2.02	2.25
% change	-	21.7%	14.7%	11.4%
P/E	39.8x	32.7x	28.5x	25.6x
FCF yield (%)	2.6%	2.9%	3.7%	4.1%
Dividends (€)	0.72	0.92	1.05	1.20
Div yield (%)	1.3%	1.6%	1.8%	2.1%
EV/Sales	3.8x	3.3x	3.0x	2.7x
EV/EBITDA	18.7x	15.3x	13.4x	12.1x
EV/EBIT	24.9x	20.3x	18.0x	16.1x

Last Friday, Luxottica announced Q4 15 adj. sales of EUR2,059m (+8.9% as reported and +2.7% adj FX-n) which came shy of CS and our expectations by ~3% only because of a higher impact from the realignment of the retail calendar and the 53rd week last year (adj FX-n growth of 7.7% excl. those calendar effects) whose impact is on U.S retail only (-2.7% adj. FX-n / +7.7% excl. calendar effect). The breaking news was clearly the departure of co-CEO for Markets Mr Khan as Mr Del Vecchio and him acknowledged that LUX was not fully capturing the significant growth prospects because of this co-CEO structure. Therefore Mr Khan will be replaced by Mr Del Vecchio whilst Mr Vian remains CEO for Product & Operations. In our view this announcement will revive some issues about the governance, especially from those who were dubious about this co-CEO structure, we adopt the same stance than during the previous "governance crisis" (Sep-Nov 2014): the business model and strategy remain sound. All eyes are now turned towards the ID on 2nd March! Our new FV of EUR65 reflects slight adjustments on our FY15-16 EBIT forecasts (-1%) but Buy recommendation reiterated.

ANALYSIS

- **Why Mr Khan resigned after just one year at the side of Massimo Vian?** According to LUX, this resignation is neither due to strategic disagreements with Chairman and Founder Mr Del Vecchio or Massimo Vian, nor by unsatisfactory results since LUX has achieved all its rule-of-thumbs and major initiatives such as the integration of Oakley's wholesale activities or the new pricing strategy in China were successfully implemented. It seems that Mr Del Vecchio and Mr Khan have both stated that this co-CEO structure model was hampering LUX's reactivity and "entrepreneurial spirit" by weighing down its decision-making process. Admittedly these arguments were emphasized by those who doubted about the effectiveness of this co-CEO model and they might consider that Mr Del Vecchio "backpedaled" on his decision to implement this new organisation. **This is why we think this announcement will again revive some concerns about the governance at the helm of Luxottica until, at least, the Investor Day (2nd March).**
- **Mr Del Vecchio was interviewed by Italian newspaper *Corriere della Sera* (29th Jan):** 1/ he confirmed that Mr Khan's departure was only due to a structure reorganisation as the group must be quicker ("more digital and simplify the decision-making process"), 2/ LUX is **about to launch a vast plan to reorganise and simplify all the commercial, marketing and markets functions by 2017**, 3/ Mr Del Vecchio intends to give up executive role after the implementation of this plan, he also specified that his successor should be chosen internally and would certainly not be one of his six children, confirming his previous commitment made in October 2014.
- **Why do we remain confident about the outlook despite this new episode?** 1/ Like in 2014, we continue to think that this new reorganisation is only at LUX's top management and should not affect the group's senior management who is responsible for the "day-to-day" operations and is key for the good execution and the achievement of the MT/LT targets, 2/ although this co-CEO model was not as efficient as initially planned, LUX achieved all its FY15 rule-of-thumbs for the sixth consecutive year, highlighting the sound and proven business model and strategy, 3/ Mr Del Vecchio is replacing Mr Khan concerning the executive responsibilities for Markets to ensure a continuity both internally and externally.
- **Q4 Wholesale sales of EUR758m (+7.7% / +7.1% adj. FX-n).** Growth was driven by a robust performance of **Europe** (~+6%) where the group enjoyed favourable weather conditions and easy comps (-8% in Q4 14). As expected, the moderate growth in the **U.S** (+2.8% vs. +7% in Q3) is justified by: (i) a very tough comparison base (+19% FX-n in Q4 14) and (ii) the integration process for Oakley's wholesale activities which might have caused minor disruptions. LUX regained some traction **Asia-Pacific** (+7.4% vs. +1.8%), partly helped by a good rebound in China following the new pricing policy since October (-10-15% on average). Last but not least, the activity in **Latin America** remained robust (+15% FX-n) irrespective of the sluggish macro environment in Brazil.
- **Q4 adj. Retail sales of EUR1,301m (+9.6% / +0.1% adj. FX-n) affected by the U.S calendar effect.** Indeed the retail calendar was nine days shorter than in Q4 14 which also enjoyed a 53rd week. Based on our estimates, **this headwind amounted to a negative sales impact of -EUR95m, or approx. 10.4 p.p. on the U.S retail adj. FX-n growth (=> +7.7% excl. the calendar effect instead of -2.7%).** Consequently LensCrafters achieved a SSSG of 1.2% (vs 3.8% in Q3) whilst **SGH** posted comps of 5.3% (vs. 6.8% in Q3). Sales at **OPSM** (Australia-NZ) declined by 1.3% same-store given the harsher competition, a price repositioning should be implemented this year.



*(To be continued next page)***Adjusted FX-neutral growth by division (%):**

Adj. FX-neutral growth *	Q3 15	9M 15	Q4 15	2015e
Wholesale division (~42% of sales)	6.8	6.9	7.1	6.9
Retail division (~58% of sales)	4.7	6.1	0.1 / 8.1 **	4.5 / 6.6 **
Group total	5.5	6.4	2.7 / 7.7 **	5.5 / 6.8 **

* Before the change in accounting method at EyeMed (FY15: -EUR174m)

Source: Company

Data

** FX-n growth excluding the retail calendar effect

- **FY15 adj. EBIT margin is set to widen 100bp to 16.3%.** Ahead of the FY15 results (1st March) we nudge down our FY15 & FY16 EBIT assumptions by 1% to reflect the lower-than-expected sales in 2015. However we leave our forecasts of margin improvement unchanged: we expect EBIT margin in the **Wholesale division** to increase 110bp (to 23.8%) while profitability in the **Retail division** should widen 90bp to 15.0%. The main margin enhancers are: **(i)** volume growth and mass scale effect, **(ii)** focus on store productivity (Retail) and **(iii)** efficiency gains at the group level. **LUX confirmed it would achieve its margin "rule-of-thumb" for the sixth consecutive year** (i.e. to grow EBIT 2x as fast as sales).

VALUATION

- **We anticipate a significant negative market reaction this morning**, which might equal the 9% drop achieved on 13th October when Mr Cavatorta resigned. As explained on the previous page, like in 2014, we maintain our positive stance since we believe than LUX will again convince investors that the business model and the growth prospects are still valid:

(i) All eyes on the Investor Day on 2nd March... Naturally investors' are looking forward to hearing the management's explanations about this reorganisation of the organisational structure, which will be at the centre of the Investor Day. Management must reassure investors by confirming his commitment to stability and continuity at the helm of the group.

(ii) ... and on fundamentals! 1/ We hope that the presentation of the "**multi-year plan**" during the ID will be convince enough to demonstrate that LUX's capacity to capture growth opportunities within the eyewear market remains intact. Key topics should be on the growth catalysts (online channel, travel retail, etc.) and on the above-mentioned reorganisation and simplification plan, while other subjects might be of interest (i.e. emphasis on ROCE/ROI ratios?, a higher shareholder return policy?). 2/ **LUX has plenty of growth opportunities for 2016**, especially in the Retail Division considering the implementation of the new store concept at LC, the partnership with Macy's and the "re-set plan" at OPSM. 2016 will probably be a milestone year in the development of **smart eyewear** (Intel and Google partnerships). 3/ **Helpful Q1 16 results** (29th April) will confirm that this new reorganisation has not affected the group's operating performance, as highlighted by the pleasing first weeks of 2016.

- **In our view, these two milestones (i.e. ID and Q1 16 results) will be crucial to ease market's concerns and prerequisites for a rebound in the share price like after the 2014 "governance crisis" when the stock rallied ~35% from 15th October 2014 until 15th January 2015.**
- We slightly adjust our FV to EUR65 vs. EUR66 to factor in minor adjustments on our FY15-16 EBIT assumptions following the negative calendar effect on the top line development.

NEXT CATALYSTS

- FY15 results to be released on 1st March // Investor Day on 2nd March.

[Click here to download](#)

Analyst:
Cédric Rossi
33(0) 1 70 36 57 25
rossi@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes
Loic Morvan
Antoine Parison
Virginie Roumage

Luxury & Consumer Goods

LVMH

Price EUR148.20

Sales growth slowdown expected in Q4 (inc at LV) and FY 50bp margin decline anticipated

Fair Value EUR182 (+23%)

BUY

Bloomberg	MC FP
Reuters	LVMH.PA
12-month High / Low (EUR)	175.6 / 134.7
Market Cap (EUR)	75,304
Ev (BG Estimates) (EUR)	78,831
Avg. 6m daily volume (000)	977.4
3y EPS CAGR	13.1%

LVMH will report its FY 15 results on Tuesday February 2nd (after market closure with analyst meeting to follow). We expect sales to reach EUR35.45bn (CS: 35.55bn) and to grow 5% organically (+3% in Q4 alone) and EBIT margin to be down 50bp to 18.2%. We reiterate our Buy recommendation with an unchanged EUR182 FV.

ANALYSIS

- The World Luxury Goods market leader will release its 2015 FY sales and results on Tuesday February 2nd after market closure (analyst meeting to follow). We expect FY sales to reach EUR35.45bn (consensus:EUR35.55bn), up 15.5% and 5% organically. This implies a 3% organic sales growth in Q4 alone following +7% in Q3 and +6% on 9M. The expected slowdown will come from Europe and US as we do not expect the same trend than on 9m (respectively +12% and +11%) given i/ the Paris attacks on November 13th that have significantly reduced tourists flows in France (7% of LVMH sales) and ii/ an environment less booming in US (lower tourists flows, consequence of a strong USD). Nevertheless, we do not anticipate further deterioration in Asia-Pacific after the 8% decline in Q3 given less demanding comparison basis in Q4 (-6% in Q4 14) and better trend in MC as already highlighted by most of luxury players. Lastly, we still expect a well oriented activity in Japan (7% of sales).
- By division, 2015 organic sales growth should be driven by Wine & Spirits (+6%) given better trend in Cognac (despite slowdown in Q4 after an exceptional Q3, and Watches & Jewelry (+9%) thanks to Bulgari while we are more cautious for F&L (+3%) and particularly in Q4 with a moderate 1.5% sales increase following +5% on 9M as Louis Vuitton momentum should be affected by November Paris attacks even if in tough period, best known brands are historically more resilient.

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.3%	-12.3%	-12.3%	2.3%
Pers & H/H Gds	-1.7%	-6.1%	-4.5%	-0.8%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	30,638	35,450	37,400	39,620
% change		15.7%	5.5%	5.9%
EBITDA	6,576	7,365	8,000	8,730
EBIT	5,716	6,465	7,050	7,730
% change		13.1%	9.0%	9.6%
Net income	2,972	3,655	4,093	4,300
% change		23.0%	12.0%	5.1%

	2014	2015e	2016e	2017e
Operating margin	18.7	18.2	18.9	19.5
Net margin	9.7	10.3	10.9	10.9
ROE	11.5	12.9	13.2	12.6
ROCE	10.3	10.1	10.6	10.7
Gearing	16.5	12.5	8.5	4.9

(EUR)	2014	2015e	2016e	2017e
EPS	5.92	7.28	8.15	8.56
% change	-	23.0%	12.0%	5.1%
P/E	25.0x	20.4x	18.2x	17.3x
FCF yield (%)	3.8%	3.4%	3.8%	4.1%
Dividends (EUR)	3.20	3.60	3.90	4.25
Div yield (%)	2.2%	2.4%	2.6%	2.9%
EV/Sales	2.6x	2.2x	2.1x	1.9x
EV/EBITDA	12.1x	10.7x	9.7x	8.8x
EV/EBIT	13.9x	12.2x	11.1x	10.0x

Organic sales growth by business

in %	H1 15	Q3 15	9M 15	Q4 15e	FY 15e
Wine & Spirits	2	16	7	4	6
Fashion & Leather	5	3	5	2	4
Perfumes & Cosmetics	6	7	7	4	6
Watches & Jewelry	10	11	10	7	9
Selective Retail	5	5	5	2	4
Group	6	7	6	3	5

Source : Company Data; Bryan Garnier & Co. ests.

- We expect LVMH 2015 EBIT to reach EUR6.46bn (CS: EUR6.52bn) up 13%, implying a 18.2% EBIT margin, down -50bp vs 2014 of which -30bp in H2 following -70bp in H1. Consensus anticipates 2015 EBIT margin at 18.3%. 2015 EBIT margin decline is due to negative hedging impact even at a less extend in H2 vs H1. Nevertheless, we expect that H2 EBIT margin should be impacted by the poor anticipated sales momentum in Q4 which accounts for almost 30% of group sales.

VALUATION

- LVMH share price has lost 12% on last three months in line with sector average and is trading 11.1x on 2016 EV/EBIT, in line with peers average. We remain Buy on the stock with an unchanged EUR182 FV.
- The clear positive catalysts at LVMH (and the reasons of our Buy recommendation) are its i/ very well balanced geographical exposure, ii/ a clear diversified businesses exposure (W&S, F&L, W&J), LVMH is not a mono business company as some others in our luxury sample, iii/ unique brands (with pricing power) in each of its business and iii/ its attractive current valuation (see above).

NEXT CATALYSTS

- FY results to be reported on February 2nd.

[Click here to download](#)



Analyst :
Loic Morvan
33(0) 1 70 36 57 24
lmorvan@bryangarnier.com

Sector Team :
Nikolaas Faes
Antoine Parison
Cédric Rossi
Virginie Roumage

Luxury & Consumer Goods

Safilo

Price EUR9.93

Safilo ended a difficult transition year, looking forward to seeing improvements in 2016!

Fair Value EUR14 (+41%)

BUY

Bloomberg	SFL IM
Reuters	SFLG.MI
12-month High / Low (EUR)	15.1 / 9.3
Market Cap (EUR)	622
Ev (BG Estimates) (EUR)	768
Avg. 6m daily volume (000)	143.1
3y EPS CAGR	10.1%

Last Friday Safilo released an unexpected FY15 preliminary sales publication. FY sales came in at EUR1,279m (+8.5% as reported and flat FX-n) in line with our forecast (EUR1,280m) but below an overly-optimistic CS (EUR1,299m). However, the quality of top line growth in Q4 was lower we expected (-2.7% FX-n vs. +1.5%e) due to North America (retail, winter sport products) and Asia-Pacific (reset plan, H-K), despite a good acceleration in Europe. Although implementing the first initiatives to strengthen the organisation (loss of Kering's small licences, new distribution model in Asia-Pacific, etc.) proved to be more painful than initially thought, we are still optimistic for 2016 given sales and margin tailwinds.

ANALYSIS

- Q4 sales of EUR319.2m up 2.6% as reported but down 2.7% FX-n. While sales matched our expectations (EUR320m), they were of lower quality given a 2.7% FX-n sales decline as softer trends in North America and a further drop in sales in Asia-Pacific dragged down the group's performance. Last but not least, Safilo's top line was also negatively impacted by the loss of three small Kering brands with the "going-forward" portfolio (i.e. excl. all Kering licences) up 2% in Q4.
- By region, note the strong acceleration in **Europe** (+11.1% FX-n vs. +5.4% in Q3) driven by all the group's key markets and Germany where the group is strengthening its presence. On the other hand, sales contracted by 3.8% in **North America** due to: (i) a weak performance by Safilo's winter sport products (Smith brand mainly) following a mild winter across the region and (ii) ongoing sluggish trends at Solstice (BG: -15-20%e) since the chain closed a few stores (out of ~125 DOS initially). However underlying trends remained robust in this region and growth prospects remain very attractive for Safilo and the rest of the industry.
- LatAm** is gradually recovering (-5.3%) after two difficult quarters, mainly driven by a strong sales development in Mexico. **Asia-Pacific** posted a worse-than-expected drop (-28.7%) as the "Reinvention Project" (i.e. new commercial and distribution model) was more difficult to implement, all the more since market conditions were more challenging, especially in China (BG: ~40-45%e of Asian sales).

	1 M	3 M	6 M	31/12/15
Absolute perf.	-8.9%	-10.3%	-13.1%	-7.3%
Consumer Gds	-4.5%	-5.3%	-4.7%	-3.4%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	1,179	1,279	1,359	1,286
% change		8.5%	6.2%	-5.3%
EBITDA	111	109	138	134
EBIT	75.3	68.2	97.5	95.5
% change		-9.3%	42.8%	-2.1%
Net income	39.0	22.5	57.6	59.5
% change		-42.3%		3.3%

	2014	2015e	2016e	2017e
Operating margin	6.4	5.3	7.2	7.4
Net margin	3.3	1.8	4.2	4.6
ROE	4.0	2.2	5.5	5.4
ROCE	4.0	3.2	5.1	5.1
Gearing	16.8	14.4	11.7	5.6

(EUR)	2014	2015e	2016e	2017e
EPS	0.71	0.39	0.92	0.95
% change	-	-46.0%	139.0%	3.3%
P/E	13.9x	25.8x	10.8x	10.4x
FCF yield (%)	NM	NM	6.0%	12.6%
Dividends (EUR)	0.10	0.13	0.16	1.16
Div yield (%)	1.0%	1.3%	1.6%	11.7%
EV/Sales	0.7x	0.6x	0.5x	0.5x
EV/EBITDA	7.1x	7.0x	5.4x	5.1x
EV/EBIT	10.4x	11.3x	7.6x	7.2x

Safilo FX-n growth by region:

% change	Q1 15	Q2 15	Q3 15	Q4 15	2015
Europe	2.8	5.4	5.4	11.1	6.0
North America	5.3	0.8	1.5	-3.8	0.8
Latin America	23.4	-6.0	-8.1	-5.3	-1.1
Asia-Pacific	-22.9	-13.4	-15.5	-28.7	-20.5
ROW	16.0	41.3	32.3	-17.1	11.6
Total	0.8	1.2	0.9	-2.7	0.0

Source: Company Data

- Showing improvements in 2016 will be crucial! The launch of the 2020 Strategic Plan proved to be more costly and difficult than initially anticipated, particularly in Asia-Pacific (~-3 p.p. impact on group's FX-n growth) where the group also faced tough market conditions. In addition to a normalisation expected in this region for 2016, Safilo can also count on other catalysts: (i) favourable momentum in the "going-forward" PF (+4.3% FX-n in 2015), (ii) launch of the Havainas licence in H2 16 (mostly in Brazil and LatAm first) and (iii) a higher contribution from the proprietary brands (especially Carrera).

VALUATION

- Although sales were in line with our expectations, we expect a negative market reaction given the weak FX-n growth in Q4 and possible downward revisions by the CS which was too optimistic
- In our view, Safilo must succeed in showing better sales and earnings momentum throughout 2016 to help regain investors' confidence.

NEXT CATALYSTS

- Safilo is due to report its FY15 results on 14th March 2016.

[Click here to download](#)



Analyst:
Cédric Rossi
33(0) 1 70 36 57 25
crossi@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes
Loïc Morvan
Antoine Parison
Virginie Roumage

Luxury & Consumer Goods

The Swatch Group

Price CHF348.40

Deterioration expected in H2

Fair Value CHF420 vs. CHF440 (+21%)

NEUTRAL

Bloomberg	UHR.VX
Reuters	UHR.VX
12-month High / Low (CHF)	445.7 / 313.9
Market Cap (CHF)	19,161
Ev (BG Estimates) (CHF)	17,978
Avg. 6m daily volume (000)	243.5
3y EPS CAGR	1.0%

The Swatch Group will release its FY 2015 sales and results during the current week (likely Thursday). Ahead of this publication, we have slightly adjusted our sales and EBIT 2015-2016 estimations following the recent poor Swiss watches exports publications. Our 2015-16 EBIT estimates have been trimmed by almost 5%. Consequently, we have reduced our FV to CHF420 from CHF440 and we remain Neutral on the stock, given still weak visibility on watches industry.

ANALYSIS

- Swatch Group is expected to release its FY 2015 sales and results in the following days (likely on Wednesday or Thursday this week). Following Swiss watches exports figures that have been released last week (-3.3% including -7% in H2), we prefer to be cautious ahead of this publication and we revise down our sales expectations by close to 2%. FY sales should reach CHF8.60bn (consensus: CHF8.66bn) and be down 1.5% on reported including -4.3% in H2 (despite easier comparison basis). **At same forex, FY 15 sales should be almost stable (+0.5%), implying 2.3% decline in H2 alone after +3.6% in H1.** FX impact should be negative close to 2.3% on FY implying around -3% in H2 (-1.4% in H1).
- Concerning watches and jewelry division, we expect FY sales to be down 1.1% to CHF8.34bn with a 0.5% increase organically implying a 2.6% decline in H2 alone (+3.4% in H1). The Swatch Group Watches & Jewelry division sales performance should nevertheless imply some market share gains vs industry trend which can be explained by the group's brands strength and in all price segments and by Harry Winston jewellery.
- Consequently, we revise down our FY 2015 EBIT by almost 4.5% and FY Group EBIT should therefore be down 13% to CHF 1.53bn (consensus: CHF1.58bn), including -16% in H2 after -8% in H1. This implies a 230bp EBIT margin decline to 17.8% (previously expected 18.5%), after -440 reported in 2014. Our FY 15 EBIT estimates imply a profitability deterioration in H2 with a 250bp decline following -200bp in H1, consequence of weaker sales momentum in H2 than in H1 and some deleverage effect, as we see likely that the Group did not take any measures to adapt its production capacity to lower sales momentum.

	1 M	3 M	6 M	31/12/15
Absolute perf.	-0.5%	-9.3%	-15.0%	-0.5%
Pers & H/H Gds	-1.7%	-6.1%	-4.5%	-0.8%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

YEnd Dec. (CHFm)	2014	2015e	2016e	2017e
Sales	8,709	8,600	9,015	9,545
% change		-1.3%	4.8%	5.9%
EBITDA	2,062	1,850	2,015	2,170
EBIT	1,752	1,530	1,690	1,835
% change		-12.7%	10.5%	8.6%
Net income	1,385	1,165	1,310	1,425
% change		-15.9%	12.4%	8.8%

	2014	2015e	2016e	2017e
Operating margin	20.1	17.8	18.7	19.2
Net margin	15.9	13.5	14.5	14.9
ROE	13.3	10.4	10.9	10.8
ROCE	15.4	12.0	12.1	11.8
Gearing	-13.0	-10.2	-8.7	-7.4

(CHF)	2014	2015e	2016e	2017e
EPS	23.38	19.67	22.11	24.05
% change		-15.9%	12.4%	8.8%
P/E	14.9x	17.7x	15.8x	14.5x
FCF yield (%)	3.4%	1.2%	1.9%	2.3%
Dividends (CHF)	7.50	7.88	8.27	8.68
Div yield (%)	2.2%	2.3%	2.4%	2.5%
EV/Sales	2.0x	2.1x	2.0x	1.9x
EV/EBITDA	8.6x	9.7x	9.0x	8.4x
EV/EBIT	10.1x	11.8x	10.7x	9.9x

Sales and EBIT adjustments

CHFm	2015 prev	2015 curr	dev %
Net sales	8 710	8 600	-1.3
o/w Watches & Prod	8 440	8 310	-1.7
Recurring EBIT	1 620	1 530	-4.5
o/w Watches & Prod	1 730	1 630	-5.5
EBIT margin (%)	18.5	17.8	-60bp
o/w Watches & Prod	20.5	19.6	-80bp

Source : Company Data; Bryan Garnier & Co. ests.

VALUATION

- Following our downwards 2015 and 2016 sales and EBIT estimates, we adjust our Fair Value from CHF440 to CHF420. We remain Neutral on the stock, despite some upside on our FV, as the visibility on the watches industry is too weak in our view and the high exposure to Greater China (35% of sales) is one of the highest in our luxury groups sample, even if we have recently seen some stabilisation or slight improvement in Mainland China. The sales momentum will still remain under pressure on coming weeks in our view. The stock is trading with a 2% discount vs peers average.

NEXT CATALYSTS

- FY 2015 results to be reported on February 3rd or 4th.

[Click here to download](#)



Analyst :
Loic Morvan
33(0) 1 70 36 57 24
lmorvan@bryangarnier.com

Sector Team :
Nikolaas Faes
Antoine Parison
Cédric Rossi
Virginie Roumagne

Construction & Building Materials

LafargeHolcim

Price CHF42.92

Current Chairman about to leave, according to the Press

Fair Value CHF60 (+40%)

SELL

Bloomberg	HOLN VX
Reuters	HOLZn.VX
12-month High / Low (CHF)	72.9 / 40.7
Market Cap (CHFm)	26,049
Avg. 6m daily volume (000)	1,810

	1 M	3 M	6 M	31/12/15
Absolute perf.	-14.4%	-22.5%	-33.3%	-14.7%
Cons & Mat	-3.7%	-1.8%	-4.5%	-3.4%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

	2014	2015e	2016e	2017e
P/E	20.8x	20.8x	13.1x	9.4x
Div yield (%)	3.0%	3.0%	3.0%	3.0%

ANALYSIS

- According to Street account, "Chairman Wolfgang Reitzle is aiming to leave his post and replace the head of Linde's supervisory board. (SonntagsZeitung reported)".
- Wolfgang Reitzle became Chairman of Holcim in 2014, approximately at the same moment the merger with Lafarge was announced. He was then co-chairman of LafargeHolcim. He was elected to the Board of Directors in 2012.
- This need to be confirmed, but it would be not a positive piece of news for LafargeHolcim. After all, CEO has been changed last year too, as well as the CFO.
- On the other hand, it will simplify the governance of LafargeHolcim, as Bruno Lafont, who was the other co-chairman, might become the only chairman (although a vice-chairman remains too).

VALUATION

- CHF60 derived from the application of historical multiples to our 2017 estimates, discounted back

NEXT CATALYSTS

- 2015 FY results on 17 March 2016

[Click here to download](#)Eric Lemarié, elemarie@bryangarnier.com

Food & Beverages

Pernod Ricard

Price EUR107.95

Acquisition of a majority stake in Monkey 47

Fair Value EUR122 (+13%)

BUY-Top Picks

Bloomberg	RI FP
Reuters	PERP.PA
12-month High / Low (EUR)	117.3 / 88.3
Market Cap (EURm)	28,652
Avg. 6m daily volume (000)	565.3

	1 M	3 M	6 M	31/12/15
Absolute perf.	1.6%	0.1%	0.0%	2.6%
Food & Bev.	-1.9%	-1.5%	1.7%	-0.7%
DJ Stoxx 600	-7.4%	-8.9%	-13.1%	-6.4%

	06/15	06/16e	06/17e	06/18e
P/E	21.6x	19.4x	18.2x	16.9x
Div yield (%)	1.7%	1.9%	2.0%	2.1%

ANALYSIS

- Last Friday, Pernod Ricard announced the purchase of a majority stake in Monkey 47's owner, Black Forest Distillers GmbH. This craft gin which is produced in the Black Forest region in Germany using 47 botanicals has gained a global following since its launch in 2010, and is now available in 50 countries across four continents. The price of the takeover has not been disclosed.
- This acquisition is no surprise since Pernod Ricard has always said that it is looking very closely at acquiring a craft spirit brand. It will extend the group's footprint in the super-premium gin category which is outpacing overall category growth. Monkey 47 is priced at around EUR50, higher than Pernod Ricard's current gin labels ie Beefeater, Plymouth and Seagram. The group said that it wants to expand the brand globally.

VALUATION

- At Friday's share price, the stock is trading at 15.8x EV/EBIT 2015/16e and 15x EV/EBIT 2016/17e, 12% and 11% below the peers' average.

NEXT CATALYSTS

- H1 2015/16 results due on February 11th

[Click here to download](#)[Virginie Roumage, vroumage@bryangarnier.com](mailto:vroumage@bryangarnier.com)

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 60.2%

NEUTRAL ratings 30.8%

SELL ratings 9%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
TMT	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
Utilities	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Insurance		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the Financial Conduct	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by	Authority (FCA) and l Autorité de		Regulated by the	Fax +91 11 2621 9062
the Financial Conduct Authority	Contrôle prudentiel et de resolution		FINMA	
(FCA)	(ACPR)			



BRYAN, GARNIER & CO

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research.

These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....